T. Rowe Price Investment Management
DNLI icon

T. Rowe Price Investment Management’s Denali Therapeutics DNLI Stock Holding History

T. Rowe Price Investment Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$416M Buy
16,178,963
+7,659,771
+90% +$157M 0.27% 95
2026
Q1 		$164M Buy
8,519,192
+1,265,060
+17% +$25.2M 0.11% 182
2025
Q4 		$120M Buy
7,254,132
+1,615,565
+29% +$27.3M 0.08% 229
2025
Q3 		$81.9M Buy
5,638,567
+2,391,633
+74% +$34.4M 0.05% 301
2025
Q2 		$45.4M Buy
+3,246,934
New +$45.7M 0.03% 406
2024
Q2 		– Sell
-498,969
Closed -$10.2M – 630
2024
Q1 		$10.2M Hold
498,969
– – 0.01% 540
2023
Q4 		$10.7M Sell
498,969
-148,044
-23% -$2.93M 0.01% 511
2023
Q3 		$13.3M Hold
647,013
– – 0.01% 509
2023
Q2 		$19.1M Hold
647,013
– – 0.01% 482
2023
Q1 		$14.9M Buy
647,013
+13,655
+2% +$376K 0.01% 493
2022
Q4 		$17.6M Buy
633,358
+211,001
+50% +$6.28M 0.01% 472
2022
Q3 		$13M Buy
+422,357
New +$13.7M 0.01% 484

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

T. Rowe Price Investment Management's DNLI Position: Q2 2026 in Review

T. Rowe Price Investment Management increased its Denali Therapeutics (DNLI) stake by 90% in Q2 2026, buying an estimated $157M and bringing the position to 16,178,963 shares worth $416M. The position accounts for 0.27% of the portfolio, ranked #95.

T. Rowe Price Investment Management first reported a position in DNLI in Q3 2022 and has held it in 12 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • T. Rowe Price Investment Management held 16,178,963 shares of Denali Therapeutics worth $416M as of Q2 2026.
  • T. Rowe Price Investment Management bought 7,659,771 Denali Therapeutics shares in Q2 2026, an estimated $157M.
  • Denali Therapeutics made up 0.27% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #95 holding.
  • T. Rowe Price Investment Management first reported a position in Denali Therapeutics in Q3 2022 and has held it in 12 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.